Get unlimited access to Bruins cup coverage - Just 99¢

The Boston Globe

Business

Boston.com

MARKET MOVERS

Dendreon’s prostate cancer drug sales soar

  January 06, 2012

Revenue from Dendreon Corp.’s prostate cancer drug Provenge more than tripled in the fourth quarter from a year earlier. The Seattle biotech said gross revenue was about $82 million. It cited a faster reimbursement time for doctors for the increase. Provenge was approved in April 2010 as the first therapy in the country that trains the body’s immune system to attack cancer cells as if they were a virus.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help

  • Phone

    888-MY-GLOBE

    Monday-Friday 6:00 a.m.- 5:00 p.m.

    Saturday, Sunday and Holidays 7:30 a.m.- 12:00 noon

  • Chat

    Start a chat

    Monday-Sunday 8:00 a.m.- 5:00 p.m.

  • E-mail

    support@bostonglobe.com